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Abstract 
 Breast cancer occurs in 1 of 8 women while 2,600 new cases of breast cancer are 
expected in men during 2016 alone1. Aromatase, a cytochrome P450 enzyme that interconverts 
androgens into estrogens, is linked to hormonal breast cancer development2. Aromatase 
inhibitors are currently used to treat breast cancer, but the mode of binding for some inhibitors 
remains unknown. The objective of this project is to optimize aromatase recombinant expression 
in E. coli and discover novel allosteric inhibitors. While screening possible new inhibitory 
compounds using an activity assay, we identified AR11 and AR13, which produced IC50 values 
of 25.35 μM and 0.41 μM respectively. We have not yet been successful in increasing 
recombinant expression of mutant-type aromatase, despite adjusting induction time, incubation 
temperature, and cell strain. Although optimization of aromatase expression was not achieved, 
possible inhibitors were uncovered which will be used in future screening of protein 
crystallization conditions once expression is improved. These crystal screens can then be used to 
generate new structures of aromatase:inhibitor complexes, leading to improved inhibitor potency 
and reduced toxicity. 
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Problem Statement 
The development of hormonal breast cancer is linked to estrogen concentrations in the 
human body2. Aromatase is the only enzyme that converts androgens into endogenous estrogens. 
Scientists are examining the structure of aromatase in order to improve their knowledge of 
inhibitor binding sites for breast cancer drug development. By doing so, they can create 
inhibitors with tighter binding for a more personalized treatment of breast cancer. 
Current aromatase inhibitors in clinical use may not have the side effects of older drugs 
such as lethargy, ataxia, and morbilliform skin rash, but they still pose an increased likelihood of 
musculoskeletal effects such as arthritis, arthralgia, and myalgia3. Some people find these side 
effects so debilitating that they become noncomplacent4. Research into aromatase continues in 
order to create better aromatase inhibitors with less severe side effects. Aromatase is an enzyme 
encoded by the gene CYP19A1, found on chromosome 15. It functions by catalyzing the 
oxidation of a methyl group to formate, followed by aromatization of the androgen to estrogen2,3. 
With detailed knowledge of the reaction mechanism, scientists are able to devise possible 
methods to inhibit the production of estrogen. An example of a clinically useful aromatase 
inhibitor is letrozole. 
Letrozole is a third-generation aromatase inhibitor that is very effective in treating 
hormonal breast cancer due to high specificity for aromatase, compared to earlier generations of 
inhibitors5. The chemical structures of several aromatase inhibitors, including letrozole, are 
presented in Figure 1. 
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Letrozole’s non-steroidal shape causes it to interact at areas outside the active site of 
aromatase. This is because letrozole’s unique shape partially mimics the steroid backbone of 
androstenedione, the enzyme’s substrate5. Even though letrozole is the most potent of the 
inhibitors being used for hormonal breast cancer treatment, there are still some side effects that 
should be resolved in order to improve its benefits over risks. These side effects include mild 
symptoms of hot flashes, vaginal dryness, and headaches along with musculoskeletal symptoms 
mentioned previously due to lack of estrogen2. Though it has only been 8 years since aromatase’s 
structure was discovered, there is still much more to be explored. New data regarding aromatase 
structure will help scientists expand the variety of aromatase inhibitors in clinical use. 
 
 
Figure 1: Molecular structures of the various aromatase 
inhibitors. The three different generations signify when the inhibitor 
was made while the various types distinguish whether it is steroidal or 
non-steroidal5. Obtained with permission of Springer. 
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Research Objective and Significance 
The goal of this project will focus on improving aromatase recombinant expression and 
finding new aromatase inhibitors. Mutant aromatase enzyme will be expressed following the Lo 
lab procedure6 and adjusted until protein expression is optimized. The mutations introduced into 
the plasmid-encoded gene include replacing 39 amino-terminal amino acids with 10 hydrophilic 
residues and adding 4 histidine residues at the C-terminus6. The final goal will be to crystallize 
the mutant enzyme with new aromatase inhibitors identified by the Ng lab via activity assays. 
This project may lead to new inhibitors of aromatase that can be used to treat hormonal breast 
cancer. 
 
Literature Review 
Introduction 
 New advances in medical research occur every day, especially in the field of breast 
cancer research. Breast cancer is the leading cause of death for women between ages 30 to 54 
and researchers are continuously working towards finding new cures to curb this disease7. 
However, there is still much to be learned about breast cancer as well as the possible methods 
that can be used to treat it. 
Aromatase and Breast Cancer 
Aromatase is an enzyme that functions in the production of estrogens by converting 
androgens through aromatization2. Androgens are a broad class of steroids that are associated as 
male sex hormones. These differ from estrogens which are associated as female sex hormones. 
Progesterone is a steroid associated with pregnancy and the menstrual cycle. All three hormones 
are found in humans and are required in varying concentrations based on sex. Cytochrome 
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P450arom and NADPH-cytochrome P450 reductase form a protein complex that regulate the 
mechanism seen in Figure 28,9. NADPH-cytochrome P450 reductase acts as an electron source 
for cytochrome P450arom to aromatize the androgen ring while cytochrome P450arom contains the 
active site for the reaction to occur3. The first two steps involve oxidation using NADPH9. The 
next step is still debated but the consensus seems to be that the ring becomes aromatic and 
Fe*O3+ is used to generate formate at the end9. A kcat of 0.06 s
−1 was reported for aromatase10. 
The small kcat means that the turnover rate of aromatase is slow, suggesting an unfavorable 
reaction. 
 
Figure 2: The mechanism of aromatase. Androstenedione, the substrate, is being converted into its product, 
estrone
9
. Step 3b is the favored mechanism. The figure is available under the terms of the ACS Editors’ Choice 
license. 
 
Various studies investigated the roles of aromatase activity and estrogen levels in breast 
cancer cells, but it was hard to reach a complete consensus on this relationship because of the 
variability exhibited between breast cancer cells. Aromatase activity and estrogen concentration 
have been shown to be inversely related to each other11. Estrogen also plays a role in producing 
growth factors in estrogen responsive tumor cells, being a potent mitogen in estrogen receptor 
(ER)-α-positive human breast cancer lines, and a key component in tumorigenesis and 
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progression of most breast cancers7,12. Cytochrome P450s have been studied in great detail, 
uncovering the various types of polymorphisms exhibited by these proteins and helping with the 
development of alternative cancer drugs that would bind to specific protein variants13. While this 
information gave researchers an understanding of aromatase function, the optimization of drugs 
that target aromatase would be facilitated by the solution of the three-dimensional structure of 
the enzyme. 
 In 2009, aromatase’s structure was finally elucidated (Figure 3). Aromatase varies from 
other cytochrome P450s proteins, as its androgen-specific active site is surrounded by 
hydrophobic and polar areas to complement the substrate’s hydrophobic nature and polar side 
chains14. In order to block this active site, aromatase inhibitors also needed hydrophobic and 
polar sites to complement the active site. Scientists could now visualize the possible binding sites 
that would inhibit estrogen production and influence breast tumor growth with the structure of 
aromatase. 
 
Figure 3: Ribbon depiction of aromatase. The first x-ray crystal structure of aromatase with bound androstenedione 
in its active site. Black is the heme cofactor, grey is the Fe2+ ion6. Obtained with permission of Springer. 
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 After discovering the structure, scientists had another hurdle to cross: expressing 
abundant amounts of stable human aromatase. As mentioned before, aromatase is a hydrophobic 
molecule with multiple polar side chains14. Because of this, it is a very unstable molecule to 
work with.  To make the purification possible, detergents or protein modifications are used to 
make it stable in vitro15,16. This is true not only for aromatase but also other P450 enzymes such 
as CYP1A2 and aldosterone synthase (CYP11B2)17,18. Even with the large amounts of research 
on P450 enzymes, there is still work to be done to optimize expression in E. coli as it is the 
cheaper alternative compared to other model organisms. 
Aromatase Drug Development 
 Aromatase inhibitors are considered the standard of care for hormone-receptor-positive 
breast cancer in postmenopausal women4. Throughout the years, aromatase inhibitors with 
higher efficacy have been designed to treat breast cancer. However, there are still improvements 
that can be made to enhance efficacy and reduce toxicity. It is known that hormonal breast 
cancer depends on estrogen concentration in breast tissue. However, estrogen production has 
implications in other health problems such as bone loss and nicotine addiction, which should be 
acknowledged in order to understand the varying effects aromatase inhibitors may have not only 
in the breast but throughout the body4,19. Because of the vast variety of side effects seen with 
aromatase inhibitors, they can be separated into two types, Types I and II, as well as three 
generations, first, second, and third generation inhibitors20. 
 Type I inhibitors, also called steroidal or orthosteric inhibitors, are a type of molecule that 
compete directly with androgen for the active site because of its chemical similarities with other 
steroid molecules3. By competing for the active site, inhibitors prevent androgens from being 
converted to estrogens by aromatase, thus slowing the growth of the breast tumor. However, 
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once the Type 1 inhibitor is bound to the active site, it cannot be released, inactivating aromatase, 
hence its other name suicide inhibitors2. Type II inhibitors, also called non-steroidal or allosteric 
inhibitors, are a type of molecule that binds to aromatase through other areas outside the active 
site3. By doing so, they can change the shape of aromatase’s active site leading to improper 
binding between the altered active site and the androgen. Because Type II inhibitors are not 
structured like other steroid molecules, the effects can be reversed depending on the amount of 
steroids present in the cell2. Though both types of inhibitors bind to aromatase in diverse ways, 
the main goal remains the same; to reduce aromatase activity, reduce estrogen concentration, and 
treat breast cancer. Figure 4 shows a diagram of the basic concepts of these processes. 
 
Figure 4: Mechanism for Type I and II inhibitors. The drawn picture shows the typical mechanism when the 
substrate, androgen, goes to the active site of the enzyme, aromatase and how the enzyme behaves when a Type I 
and Type II inhibitor is introduced to the reaction. The substrate in both cases cannot bind to the active site. 
 
 First, second, and third generation inhibitors are categorized based on when they were 
developed20. The primary first generation drug used to treat breast cancer was aminoglutethimide 
(AG), a Type II inhibitor. It was discontinued from use because of its low binding specificity to 
aromatase, leading to drug toxicity due to its interactions with other enzymes in endocrine 
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systems such as cortisol and aldosterone biosynthesis2,20. A new generation of drugs were created 
to fix this problem named second generation inhibitors. The primary second generation drug in 
use was 4-hydroxyandrostenedione (formestane), a Type I inhibitor that was more effective than 
AG but still produced some side effects2. Formestane also required intramuscular injection, 
making it harder to distribute compared to oral tablets20. Since their cons outweighed the pros, 
second generation drugs were eventually phased out in favor of third generation drugs for breast 
cancer treatment. The third generation cancer drug primarily used now is letrozole, a Type II 
inhibitor that is considered the most potent breast cancer drug. The reason it is more effective is 
because of its minimal effects on other endocrine systems in the body, while still inhibiting 
aromatase present in the peripheral tissue of breast cancer cells4,5. Even though aromatase 
inhibitors are the first line of defense in hormonal breast cancer, there is still the possibility of 
drug resistance occurring. 
Drug resistance occurs when a drug becomes ineffective in treating the disease it was 
created to defeat. In this case, aromatase inhibitors are slowly becoming resistant to breast cancer 
cells, making it harder to find new drugs that can combat this trend. One way to combat it would 
be to understand the mechanisms that control this process. In one experiment, mice were treated 
with letrozole until their tumors became drug resistant. By doing so, they found that tyrosine 
kinase receptors, HER-2, adapter proteins (p-Shc and Grb-2), and all of the signaling proteins in 
the MAPK cascade were increased in tumors resistant to letrozole21. By knowing this, scientists 
can devise new drugs that can decrease the production of these proteins. Another way to 
overcome drug resistance for aromatase inhibitors would be to study patient pharmacogenomics. 
By screening patients to obtain their genomic file, physicians can have a better idea on which 
drug is best suited to the patient so that it avoids side effects and is effective22. As the knowledge 
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of aromatase inhibitors and the effects they produce in patients’ bodies expand, there is still room 
for improvement to create better drugs for breast cancer treatment.  
 
Methods 
Overview 
 Mutant-type aromatase will be expressed and optimized in E. coli by adjusting induction 
time, incubation temperature, and cell strain from an already established protocol from the Lo 
lab6. Various inhibitors will also be screened using a CYP19 activity assay to identify potential 
inhibitors to test against aromatase. The long-term goal is to co-crystallize mutant aromatase 
with inhibitors of high potency. 
Conventional Cloning 
The mutant-type aromatase was produced via conventional cloning. This process consists 
of three main steps; creating the DNA insertion, inserting the DNA insert into a plasmid, and 
introducing the plasmid into E. coli. The aromatase insert, obtained from GenScript, was created 
by deleting 39 N-terminal amino acids from human aromatase, replacing them with 10 
hydrophilic N-terminal residues, and adding 4 histidine residues at the C-terminus6 (Figure 5). 
 
Figure 5: Sequence of original aromatase (above) and aromatase insert (below). The entire amino acid sequence 
of human aromatase with the 39 amino acids in blue represented the section to be deleted. For the recombinant 
aromatase, there was the addition of 10 hydrophilic amino acids on the N-terminus and 4 histidines on the C-
terminus shown in red6. 
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The 39 amino acids were deleted and replaced with 10 hydrophilic amino acids at the N-
terminus to remove the predicted transmembrane domain, decreasing the likelihood of protein 
aggregation. The C-terminus had 4 histidine residues added to create a His-tag, making the 
protein easier to identify using Western blots and purify during the purification process. The 
cloning process was attempted many times in the lab with minimal success so it was decided to 
order the plasmid from GenScript to obtain the aromatase construct and proceed with the 
experiment. There were three attempts using a different vector, pCWori-A13AMO‐aaCPRct, 
before a new plasmid was ordered from GenScript. The first attempt failed as the vector being 
used to clone the insert had an unknown size and sequence, making it hard to determine which 
construct was the correct one. The second attempt looked at dephosphorylating the vector to see 
if this would optimize ligation. Growth was still not seen on the plates. During the third attempt, 
an incorrect primer was discovered. However, the DNA concentration after PCR was still low. 
Since it was low, the construct could not be created as there was not enough of the insert to work 
with. The new plasmid construct contains the aromatase insert, replacing SacB in the pCW-LIC 
vector, which confers ampicillin resistance. Figure 6 shows the original plasmid. 
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Figure 6: Diagram of pCW-LIC construct from GenBank. Construct contains 2 active taq promoters, an origin 
of replication (ORI), ampicillin (AMP) resistance, restriction sites, and a SacB gene which gets replaced with the 
aromatase insert. 
 
Expression and Purification 
The pCW-LIC expression plasmid, containing the aromatase insert, was used for cloning 
and transformed in E. cloni 10G competent cells. Rosetta2 E. coli cells were transformed with 
the aromatase construct and an expression vector containing HemH. HemH is the gene that 
encoded ferrochelatase, the enzyme that catalyzes the last step of heme biosynthesis23. The 
transformed cells were then plated on solid media mixed with antibiotics, carbenicillin and 
kanamycin. After overnight growth, one colony was isolated from the plate and resuspended in 2 
mL of lysogeny broth (LB) with 2 µL 1,000X carbenicillin and kanamycin. After 16 hrs of 
growth overnight at 37°C with shaking, the cells were transferred into 100 mL of terrific broth 
(TB) and grown at 37°C with shaking at 250 rpm until the optimal density (OD) read between 
0.5-0.8 at 600 nm. The temperature was dropped to 18°C and incubated for 1 hr. Following the 
incubation, 5 µM FeCl3, 1 mM δ-ALA1, 1 mM IPTG and additional carbenicillin and kanomycin 
were added to the culture and grown for 48 hrs with continued shaking at 250 rpm. The cells 
were then harvested with a lysis buffer and centrifuged at 4,700 rpm for 10 min. The remaining 
pellet was washed 3 times using lysis buffer with 10X the pellet volume and stored in -80°C until 
later use. The pellet was resuspended in lysis buffer, lysed through sonication, and centrifuged at 
20,000 g for 30 min at 4°C to attain the proteins soluble in the cell supernatant. Nickel affinity 
chromatography was used to separate mutant-type aromatase from its cellular debris with a wash 
and elution buffer. Aromatase has a molecular weight of 55 kDa19. SDS-PAGE and Western 
Blotting was used to confirm the presence of aromatase based on its size and presence of a His-
tag. 
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Bioassays 
The pure protein was characterized using an in vitro assay. The CYP19/MFC High 
Throughput Inhibitor Screening kit (Corning) was used to test aromatase activity. The kit 
provided native CYP19, 7-methoxy-4-trifluoromethyl coumarin (MFC), ketoconazole (KTZ), 
control protein, buffers, and cofactors. MFC is a fluorescent substrate that reacts with CYP19. 
KTZ is a positive control that inhibits CYP19 activity. The reaction involves CYP19 converting 
MFC into 7-hydroxy-4-trifluoromethyl coumarin (HFC). Since HFC is a fluorescent product, its 
activity can be measured by the intensity of the product. When an inhibitor such as KTZ is 
introduced into the system, it blocks the reactions from occurring; thus limiting product 
formation and the intensity of the fluorescence. Using this principle, multiple inhibitors were 
tested on the kit to determine its inhibitory concentration at 50% (IC50) based on its fluorescence 
measured with a plate reader. Unfortunately, time constrains hindered the crystal screening 
portion of the experiment so crystals were not made. This would be the next step of the overall 
project. 
 
 Results and Discussion 
Inhibition Assays 
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Figure 7: CYP19 Inhibition Assay with AR11, AR12, and AR13. AR11, AR12, and AR13were run against 
positive controls, ketoconazole (KTZ) and endoxifen (END), to test the effectiveness of the new inhibitors. 
 
 
Figure 8: CYP19 Inhibition Assay with AR11 and AR13 analogs. AR11-2, an analog of AR11, and RN1, an 
AR13analog, were run against positive controls, KTZ and AR13, to test the effectiveness of the new inhibitors. 
 
 Three potential allosteric inhibitors, AR11, AR12, and AR13, were screened using the 
CYP19/MFC High Throughput Inhibitor Screening kit (Corning). They were run against 
ketoconazole (KTZ), a positive control from the kit, and endoxifen (END), a known aromatase 
inhibitor. A FluoDia T70 plate reader was used to measure aromatase activity from the 
fluorescent substrate 7-methoxy-4-trifluoromethyl coumarin (MFC) to 7-hydroxy-4-
trifluoromethyl coumarin (HFC). The data was run in duplicate and averaged from two cycles. 
The inhibitors had a concentration of 25 µM in the first well. It is important to note that IC50 
values are not concrete values as they change with varying conditions, especially the substrate 
affinity and whether the inhibitors are competitive or uncompetitive. IC50 values are only able to 
tell us the relative potencies of the various inhibitors being studied. 
AR12 did not show significant inhibition. This suggests that it would not be a potent 
inhibitor as it would require a high dosage in order to be effective. AR11 produced an IC50 value 
of 25.35 μM, similar to END. AR13 produced an IC50 value of 0.41 μM, which was lower than 
KTZ. AR11 and AR13 had promising results as they performed at or better than the positive 
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controls that were being tested. The data also suggests that they would also require a normal or 
lower dosage, which is ideal when developing new drugs with reduced side effects.  
Analogs of AR11 and AR13, AR11-2 and RN1, were then tested to determine if shape 
was the main contributor towards inhibitor potency. The IC50 value of AR11-2 was not obtained 
as it produced a large curve meaning this analog of AR11 was not potent. RN1 was not as potent 
as AR13 since it had a larger curve compared to AR13. It was determined that the inhibitor’s 
binding affinities, not the structure, were causing the large changes in potency between the 
analogs. Once the allosteric inhibitors were chosen for future crystallization experiments, we 
focused on expression of mutant aromatase. 
Co-Expression of CYP19/HemH in Rosetta2 Cells 
 
Figure 9: Gel Electrophoresis of Aromatase Plasmid Mini Prep. Lane 1: GeneRuler 1kb Ladder, Lane 2: Diluted 
Aromatase Construct from GenScript (120ng/mL), Lane 3 & 4: Human Aromatase (CYP19) Plasmid from Mini 
Prep DH5α cells. 
 
To determine the presence of the gene insert in the plasmid, gel electrophoresis was run. 
Figure 9 showed the presence of 4 bands in the original diluted plasmid while only 2 distinct 
bands from the Mini Prep. However, the 2 bands corresponded with the bands present in the 
original construct so it was decided that the expression be continued as the plasmids obtained 
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from the Mini Prep were clean. More attention was paid towards the expression process as the 
difference in bands may imply improper protein expression and formation. 
When aromatase (CYP19) and ferrochelatase (HemH) were co-expressed using two 
plasmids in Rosetta2 E. coli competent cells, the protein was not seen after Nickel affinity 
chromatography in Figure 10. The ladder was not helpful as it smeared from being in the first 
lane so only rough estimates could be made from the bands. It is important to note that Lane 5 is 
similar to Lane 4 because of residual protein being removed from the first wash. Lanes 8-9 also 
saw residual protein being removed from the first elution compared to Lane 7. There were some 
faint bands seen in Lanes 2-9 with Lanes 2-5 showing an additional band present in the lanes. 
Possible options for the different bands could be HemH (36 kDa monomer), ampicillin (AMP) 
(27 kDa), and chloramphenicol acetyltransferase (CAT) (26 kDa) as E. coli can express these 
enzymes from the plasmids construct they obtained. 
 
Figure 10: SDS-PAGE of Aromatase after His-Nickel Affinity Chromatography. Lane 1: PageRuler Prestained 
Protein Ladder, Lane 2: Pellet, Lane 3: Supernatant/Crude, Lane 4: Flow-through from chromatography, Lane 5-7: 
Washes from chromatography (3 times), Lane 8-13: Elution from chromatography (6 times). The co-expression of 
CYP19/HemH with Rosetta2 cells was used for this run. 
 
CYP19 
 
 
16 
 
A possibility for CYP19 not expressing could arise from the co-expression of two 
different plasmids. The HemH construct was ordered from GenScript. It originated from the pET 
vector and contains a T7 promoter, kanamycin (KAN) resistance, and an origin of replication 
(ORI). The CYP19 construct was also ordered from GenScript and originated from the pCWori+ 
vector. It contains a taq promoter, ampicillin (AMP) resistance, and an ORI. Looking at two 
constructs, one cause of discrepancy could arise from the ORI. Since the specific identity of the 
ORI is vague, it could be that the two plasmids have the same ORI. This could cause the bacteria 
to kick one of the plasmids out leaving the other plasmid behind for expression. It is also 
important to mention that the taq promoter is not as efficient as the T7 promoter as it is leaky 
suggesting expression of CYP19 may not be optimal. 
Co-expression of CYP19 and HemH will be grown at the same time as the aromatase. If 
the CYP19 plasmid was disfavored during the co-expression, the two samples would show 
different protein results. If the plasmids were still present in the co-expression, then the two 
samples would have the same protein but be expressed at different concentrations. If the co-
expression was not working properly, a new construct should be made where HemH and CYP19 
are present in one plasmid to avoid the possibility of plasmid favoring. 
Another reason CYP19 is not expressing could be from an improper sequence. Since the 
construct was made by the company Genscript, it was assumed that the sequence was correctly 
inserted inside the plasmid. However, nothing is confirmed unless the plasmid is actually 
sequenced. To test whether the correct sequence was inserted inside, the beginning and end of 
the CYP19 insert was sequenced and compared to the original template used. If there were errors 
at the ends, it was assumed construct was incorrectly made. If there were no mistakes, it meant 
that the construct was made correctly. 
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Figure 11: Second Run of Aromatase after His-Nickel Affinity Chromatography with SDS-PAGE. Lane 1: 
empty, Lane 2: PageRuler Prestained Protein Ladder, Lane 3: 2% SDS CYP19 pellet, Lane 4: 2% SDS 
CYP19/HemH pellet, Lane 5: Elution 1 CYP19, Lane 6: Elution 1 CYP19/HemH, Lane 7: Elution 2 CYP19, Lane 8: 
Elution 2 CYP19/HemH, Lane 9: CYP19 pellet with 4X loading dye, Lane 10: CYP19/HemH pellet with 4X 
loading dye, Lane 11: Ni-HRP Positive Control. 
 
 
Figure 12: Second Run of Aromatase after His-Nickel Affinity Chromatography with Western Blot. Lane 1: 
empty, Lane 2: PageRuler Prestained Protein Ladder, Lane 3: 2% SDS CYP19 pellet, Lane 4: 2% SDS 
CYP19/HemH pellet, Lane 5: Elution 1 CYP19, Lane 6: Elution 1 CYP19/HemH, Lane 7: Elution 2 CYP19, Lane 8: 
Elution 2 CYP19/HemH, Lane 9: CYP19 pellet with 4X loading dye, Lane 10: CYP19/HemH pellet with 4X 
loading dye, Lane 11: Ni-HRP Positive Control.  
 
Figure 11 and 12 showed the results of the purification from the second transformation of 
CYP19/HemH and CYP19 in Rosetta2 cells. CYP19 was present in the elutions of the SDS-
CYP19 
CYP19 
1   2    3   4    5    6    7    8    9   10   11 
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PAGE as there were bands at 55 kDa but are not visible in the Western blot. This suggests that 
the CYP19 HIS-tag is strong enough to be separated from other HIS-tagged proteins in the 
purification step but not strong enough to attach to the Nickel-Horseradish Peroxidase (Ni-HRP) 
probe used to visual the Western blot. The CYP19/HemH expression also produced less protein 
than the CYP19 expression as seen in the gel and varying pellets colors. CYP19/HemH produced 
a brown pellet while CYP19 produced a red pellet, the ideal color after iron incorporation in 
aromatase. CYP19 was not in the pellet after solublizing with 2% SDS and no significant bands 
were seen at 55 kDa. 
The Western reaffirmed that other HIS-tagged proteins are present in the expression as 
there were visible bands above 25 kDa. The sequencing data of CYP19 plasmid and CYP19 Mini 
Prep were also obtained. The forward sequences were successful while the reverse sequences 
were not. Since the reverse primers were causing issues, a different primer was used to assure the 
HIS-tag was present in the construct as the successful forward sequence confirmed CYP19 was 
inserted into pCW-LIC. A forward primer that bound to the nucleotide 1,230 of the insert was 
used to bind near the end to confirm the presence and length of the HIS-tag attached to CYP19. 
From the data collected so far, it was decided to test time points of the expression with 
retransformed CYP19 cells as it seemed to produce more protein than the CYP19/HemH co-
expression. 
 CYP19 in Rosetta2 cells were grown under normal conditions and 100 mL samples were 
taken starting from 18 hrs. This continued every 6 hrs instead of harvesting the cells after 48 hr 
to observe the varying amounts of protein being produced at each time point. However, the 
results of the time trials were inconclusive as the samples were found not shaking until 18 hrs 
after initial growth. Because of this, it was decided to toss all samples except 48 hrs in order to 
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perform a tryptic digest. This was done to determine whether there was functional protein 
present in the culture, even without the required shaking. Unfortunately, the tryptic digest did not 
work so the data was not very informative. The sequencing data told us that the His-tag was 
inserted correctly as the 4 histidine residues were seen in the sequence data. A different antibody 
should be used to detect 4 histidine residues specifically as the current probe can only detect 6 
histidine residues. Since the time trials were uninformative, the next variable to focus on was 
growth temperature. Two cultures were grown normally with the only difference being 
temperature. One flask would be grown at 28°C and while the other grown at 18°C. 
Temperature Modifications for CYP19 Expression in Rosetta2 Cells 
 
Figure 13: SDS-PAGE of Aromatase Temperature Trials after His-Nickel Affinity Chromatography. Lane 1: 
empty, Lane 2: PageRuler Prestained Protein Ladder, Lane 3-5: Elutions from cells grown at 18°C (3 times), Lane 6: 
Supernatant/Crude from cells grown at 28°C, Lane 7: Flow-through from cells grown at 28°C, Lane 8: Wash from 
cells grown at 28°C, Lane 9-11: Elutions from cell grown at 28°C (3 times), Lane 12: empty, Lane 13: PageRuler 
Prestained Protein Ladder. 
 
Figure 13 depicts elevated expression levels at 28°C over 18°C. This was indicated by 
increased intensity of the gel band. Furthermore, the mass of the cell pellet after harvest was 
greater and it exhibited a deeper red color. Only part of the purification from the 18°C growth 
was run on a Western blot while the 28°C growth was examined in more detailed. From the 
Western blot, contaminants were seen at 180 kDa since there was a strong band at that molecular 
weight. A possible contaminant at 180 kDa could be RNase E as it falls in the same size and is 
CYP19 
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present in bacterial expression. There also seemed to be faint bands present in the elutions at 55 
kDa suggesting the production of CYP19. However, 55 kDa should be the strongest band and not 
the contaminant at 180 kDa. A new purification method was tested since the His-tag bound 
poorly to the Ni-HRP used to visualize the Western blot. It was assumed that the His-tag on 
CYP19 might not attach to the Nickel affinity chromatography correctly since it had a weak 
affinity for 4 histidine residues, causing some of the protein to be lost in the wash and flow-
through. The reason for preferential growth at 28°C comes from a higher optimal growth density 
at higher temperatures than at lower temperatures. While growth at a lower temperature produces 
more functional protein as it insures slow peptide folding and incorporation, it does inhibit some 
protein production. To fully confirm the production of CYP19, 2 vials of cells would be grown at 
28°C for 48 hrs with the only difference being the presence or absence of IPTG to induce the 
cells. 
Induction Tests for CYP19 Expression in DH5α Cells 
When the cells were grown in the following conditions, there was no protein present in 
either sample. It is interesting to note that the uninduced cells had the correct supernatant color 
of a red hue even though the pellet was much larger and chunkier than the induced cells. The 
reason could arise from the presence of iron in the media as it may not have been incorporated 
properly into the protein. After concentrating both samples, the gel seemed to be inconclusive as 
there were lots of contaminants present but CYP19 was nowhere to be found. It was decided to 
reattempt the co-expression of CYP19 and HemH in DH5α E. coli competent cells and perform 
colony-PCR to test whether the samples being grown had the insert present. 
 
 
21 
 
 
Figure 14: Gel Electrophoresis of Colony PCR with CYP19 and CYP19/HemH Colonies in DH5α. Lane 1: 
GeneRuler 1kb Ladder, Lane 2-4: Three different colonies from CYP19 plate (A1, B1, C1), Lane 5-7: Three 
different colonies from CYP19/HemH plate (A2, B2, C2). 
 
 
Figure 15: SDS-PAGE of CYP19 and CYP19/HemH alongside CYP19 with and without IPTG induction in 
DH5α. Lane 1: PageRuler Prestained Protein Ladder, Lane 2: CYP19 pellet, Lane 3: CYP19 supernatant, Lane 4: 
CYP19/HemH pellet, Lane 5: CYP19/HemH supernatant, Lane 6: PageRuler Prestained Protein Ladder, Lane 7: 
CYP19 with IPTG pellet, Lane 8: CYP19 pellet without IPTG, Lane 9: CYP19 with IPTG supernatant, Lane 10: 
CYP19 without IPTG supernatant, Lane 11: PageRuler Prestained Protein Ladder. 
 
A new plate of CYP19 and CYP19/HemH was expressed on their respective antibiotic 
plates. After incubating, 3 colonies from each plate were picked and used to run colony-PCR. Of 
the 6 samples, only 2 colonies had inserts at 1.5 kb. This was concerning as all of the samples 
were expected to contain the insert but the experiment was continued and the issue noted. Using 
CYP19 
                      CYP19 
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the 2 colonies, CYP19 and CYP19/HemH were grown in 50 mL of TB and washed with 
phosphate buffer, pH 7.4. The cells were also solubilized with 1 mg/mL lysosyme and 1% 
Tween20 to help lyse the cells open. The pellet and supernatant were analyzed using SDS-PAGE 
and Western blot. Ni-HRP and Anti-Aromatase antibodies were tested on the Western blots to 
determine the presence of CYP19 in the supernatant. Since the Western blots failed to show any 
bands, it was not included in the data. It was also decided that the Anti-Aromatase antibody 
would be for future Western blot development as it would be more CYP19-specific compared to 
the Ni-HRP. 
 
Figure 16: Gel Electrophoresis of Colony PCR with CYP19 in DH5α. Lane 1: GeneRuler 1kb Ladder, Lane 2-4: 
Three different colonies from CYP19 plate (A, B, C). 
 
Colony-PCR was repeated on CYP19 as all of colony B1 from the previous experiment 
was used up before being plated. The results were more worrisome as the bands were at 1 kb 
instead of 1.5 kb. However, since it was the only band present and a 1.5 kb band was present in 
the previous PCR, the experiment continued on. It is also important to note that it could have 
been the use of a different ladder that was giving different band sizes. Since there was still no 
progress in expression and visualization of CYP19, it was decided to induce the cells again in the 
presence and absence of IPTG but maintain the temperature at 37°C. 
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Figure 17: SDS-PAGE of CYP19 with and without IPTG induction in DH5α. Lane 1: PageRuler Prestained 
Protein Ladder, Lane 2: CYP19 pellet with IPTG, Lane 3: CYP19 pellet without IPTG, Lane 4: CYP19 supernatant 
with IPTG, Lane 5: CYP19 supernatant without IPTG, Lane 6: PageRuler Prestained Protein Ladder. 
 
 The reason for maintaining the induction at a high temperature was to see if CYP19 was 
being produced. Even if inclusion bodies and inactive protein formed, the goal was to see if 
anything was being made. If nothing was found in the SDS-PAGE and Western blot, it could be 
assumed that the promoter was not functioning properly. This meant that a new construct of 
CYP19 should be made and the experiments repeated. The pellet and supernatant of this 
experiment were run on the same gel (Figure 17) with the previous experiment so a side-by-side 
comparison could be done. The SDS-PAGE and Western blot for all of the samples being tested 
did not show any signs of aromatase. However, there was a large band around 15 kDa on the 
SDS-PAGE. This is interesting as there was nothing seen in the Western blot at the size. Another 
interesting note is that the cells induced with IPTG looked exactly like the cells without IPTG 
induction in terms of protein expression. This suggests that the promoter may not be functioning 
properly so a sequence was done on the construct to see if this was the case. 
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Basal Expression Levels for CYP19 in Rosetta2 Cells 
 
Figure 18: Gel Electrophoresis of Colony PCR with CYP19 and pCW-LIC in Rosetta2. Lane 1: GeneRuler 1kb 
Ladder, Lane 2-4: Three different colonies from CYP19 plate (A, B, C), Lane 5-7: Three different colonies from 
pCW-LIC plate (A, B, C). 
 
 
Figure 19: SDS-PAGE with CYP19 and pCW-LIC in Rosetta2. Lane 1: PageRuler Prestained Protein Ladder, 
Lane 2: CYP19 with IPTG pellet, Lane 3: CYP19 without IPTG pellet, Lane 4: pCW-LIC (B) pellet, Lane 5: pCW-
LIC (C) pellet, Lane 6: CYP19 with IPTG supernatant, Lane 7: CYP19 without IPTG supernatant, Lane 8: pCW-
LIC (B) supernatant, Lane 9: pCW-LIC (C) supernatant, Lane 10: PageRuler Prestained Protein Ladder. 
 
 The final step was to compare CYP19 to the empty pCW-LIC vector in Rosetta2 cells to 
confirm the construct was not working properly. The reason for the change in cell strain is 
because DH5α is used primarily for cloning instead of expression. Since Rosetta2 is a strain used 
specifically for expression, it could tell us whether cell strain was the issue or if the vector itself 
was defective. The cells were transformed and colony-PCR was run to ensure the transformation 
worked. It was expected that bands would be present in CYP19 and not the vector as it should 
not contain the insert. However, the gel seemed to show a strong band in Lane 7 and faint bands 
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in Lane 5-6 for pCW-LIC. Because of this, two negative controls (colony B and C from pCW-
LIC) were expressed alongside colony B from CYP19 and induced at 37°C to confirm CYP19 
was being produced in the cells. 
 Observing Figure 19, all of the samples looked identical. There was also no band at 55 
kDa but a large band at 15 kDa suggesting the presence of contaminants. This protein could have 
been chaperonin 10 (GroES) as the high induction temperatures may have caused the protein to 
shift down the gel. GroES is an important protein that works in conjunction with chaperonin 60 
(GroEL) for proper protein folding. Since GroEL was not seen in the gel but GroES was, it could 
be that the bacteria were not producing it. If the bacteria were only producing one of the two 
major protein chaperones, it could be that CYP19 was being made but not being folded correctly. 
Examining the sequencing results of the promoter, it was determined to be mutation-free. It was 
decided that a new vector should be constructed and the experiments performed would be done 
again. 
 
Conclusions 
 Overall, novel allosteric inhibitors were discovered and expression conditions for 
aromatase tested. AR11 and AR13 showed promising results as possible aromatase inhibitors but 
needed further studies to confirm this. Co-expression of CYP19 and HemH did not show 
improved expression of CYP19. Increased incubation time showed that longer induction time 
increased protein expression though it could be from increased cell density. Increases in 
induction temperature showed increased protein expression though this could also be from 
increased cell density. Changes in cell strain showed no difference in protein expression so 
Rosetta2 competent cells were still used as they were expression-specific. Induction studies 
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showed no difference in protein expression either, suggesting a mutation in the promoter region 
which could affect CYP19 expression. However, the promoter showed no signs of mutations 
suggesting a different issue in cloning occurred. For future studies, it is hoped that aromatase 
will be expressed and purified in ample amounts using a new construct. More assays should also 
be run to determine the modality and 𝐾𝐼 of the newfound inhibitors. Finally, co-crystallization of 
mutant aromatase to said inhibitors should be created via crystal screens and their crystal 
structure determined so more aromatase structures can be obtained. 
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